choline chloride — Interim data
Q4 2026
We look forward to reporting interim results from the Phase 2b dosing cohort of THRIVE-3 in the fourth quarter of this year.Source filing
TARA biotech catalysts & pipeline
PROTARA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
TARA-002 — NDA/BLA submission
H2 2027
Based on engagement with the FDA under Breakthrough Therapy designation, the Company intends to submit a BLA for TARA-002 in LMs based on the results of the pivotal STARBORN-1 trial in the second half of 2027 and will continue to submit safety and efficacy data from the trial on an ongoing basis to support the FDA's evaluation of the risks and benefits of TARA-002 in LMs.Source filing